Posted inComunicati
Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to…









